Sign In
Buy ITOS
$10.15
+0 (+0%)
At Close: Nov 28, 2025
iTeos Therapeutics: Decimated By Collateral Events, Good Chances Of Success Nevertheless
11:00am, Thursday, 27'th Feb 2025
iTeos' lead molecule, Belrestotug, shows promising efficacy in trials despite setbacks in the anti-TIGIT space, with significant partnerships and a strong cash position. The stock has suffered due to
All You Need to Know About iTeos Therapeutics (ITOS) Rating Upgrade to Buy
01:01pm, Monday, 13'th Jan 2025
iTeos Therapeutics (ITOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
iTeos Therapeutics: A Perhaps Unjustified Decline To End 2024
07:01pm, Tuesday, 17'th Dec 2024
iTeos Therapeutics, Inc.'s lead candidate, belrestotug, shows promising response rates in lung cancer but faces challenges with increased toxicity and skepticism due to past failures in similar approa
- Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate (ORR) and a median PFS of 7.7 months for all evaluable patients across the cohorts - Recommen
iTeos to Participate in Upcoming Investor Conferences
07:00am, Tuesday, 26'th Nov 2024
WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 26, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development
iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates
07:00am, Tuesday, 12'th Nov 2024
- EMA granted clearance to advance belrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in the EU - Interim data from inupadenant Phase 2 A2A-005 i
Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths
01:05pm, Monday, 16'th Sep 2024
Biotech stocks Nuvalent and Iteos diverged Monday on updates for their lung cancer treatments at the ESMO meeting in Madrid.
iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
08:44am, Monday, 16'th Sep 2024
U.S. stock futures were mixed this morning, with the Dow futures gaining around 100 points on Monday.
iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGIT
03:37am, Sunday, 15'th Sep 2024
iTeos Therapeutics' belrestotug shows promising response rates in lung cancer trials, especially when combined with dostarlimab, despite significant safety concerns. Financially, ITOS has over 3 years
- Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose - >30% cORR difference betwee
iTeos to Participate in Upcoming Investor Conferences
04:30pm, Wednesday, 28'th Aug 2024
WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 28, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery an
WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 20, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery an
ITeos Therapeutics, Inc. (ITOS) Reports Q2 Loss, Tops Revenue Estimates
09:21am, Thursday, 08'th Aug 2024
ITeos Therapeutics, Inc. (ITOS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to loss of $0.96 per share a year ago.
iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer
07:00am, Monday, 05'th Aug 2024
WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 05, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery
iTeos Therapeutics: Rippling Waves Of TIGIT Pessimism
09:00pm, Monday, 08'th Jul 2024
iTeos Therapeutics is developing an anti-TIGIT molecule for various cancers, partnering with GSK and advancing to late-stage clinical studies. Their main clinical focus is belrestotug, aiming to diffe
